ELOXX PHARMACEUTICALS, INC. Accretion Expense
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Accretion Expense of $122.82 thousand for the 3-month period ending 2017-09-30, per its 10-Q filed 2017-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2017-11-14
- ELOXX PHARMACEUTICALS, INC. accretion expense for the quarter ending 2017-09-30 was $122.82K.
- ELOXX PHARMACEUTICALS, INC. accretion expense for the quarter ending 2017-06-30 was $195.84K.
- ELOXX PHARMACEUTICALS, INC. accretion expense for fiscal 2017 was $241.73K.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2017-09-30 | $122.82K 10-Q · filed 2017-11-14 | $318.67K derived: sum of 2 quarters · filed 2017-11-14 | ||
| 2017-06-30 | $195.84K derived: 10-K 12 month − 10-Q 9 month · filed 2017-10-13 | $241.73K 10-K · filed 2017-10-13 | ||
| 2017-03-31 | $45.88K 10-Q · filed 2017-05-22 | |||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |